Quick Answer
Definium Therapeutics, Inc. reported Research And Development Expense of $117.67 million for the year ending 2025.
- Definium Therapeutics, Inc. showed an increase of +80.2% in Research And Development Expense from 2024 to 2025.
- This data is from Definium Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $6.81 million | Q2 2021: $8.07 million | Q3 2021: $9.02 million | Q1 2022: $10.24 million | Q2 2022: $9.33 million | Q3 2022: $7.77 million | Q1 2023: $12.60 million | Q2 2023: $14.78 million | Q3 2023: $13.20 million | Q1 2024: $11.71 million | Q2 2024: $14.65 million | Q3 2024: $17.19 million | Q1 2025: $23.36 million | Q2 2025: $29.81 million | Q3 2025: $30.98 million.
- Over the full 6 years of available data (2020 to 2025), Definium Therapeutics, Inc.'s Research And Development Expense has grown by 531.6%.
- Historical annual values: Fiscal year 2025: $117.67 million | Fiscal year 2024: $65.30 million | Fiscal year 2023: $52.12 million | Fiscal year 2022: $36.17 million | Fiscal year 2021: $34.79 million | Fiscal year 2020: $18.63 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: